Pharsight

Spravato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2027

(2 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(8 years from now)

US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(9 years from now)

US11311500 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US11883526 JANSSEN PHARMS Esketamine for the treatment of depression
Feb, 2040

(15 years from now)

Spravato is owned by Janssen Pharms.

Spravato contains Esketamine Hydrochloride.

Spravato has a total of 7 drug patents out of which 0 drug patents have expired.

Spravato was authorised for market use on 05 March, 2019.

Spravato is available in spray;nasal dosage forms.

Spravato can be used as treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant, treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant, treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks, treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant, treatment of trd with nasally administered esketamine in conjunction with an oad in a patient who has missed a dose during the maintenance phase and had worsening of depression symptom by returning to higher dosing schedule, treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant.

The generics of Spravato are possible to be released after 18 February, 2040.

Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Mar 05, 2024
New Indication(I-840) Jul 31, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketami...

Dosage: SPRAY;NASAL

How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage

SPRAVATO family patents

Family Patents